| Unbound MEDLINE results for: | Bookmark this site | | Articles related to 8831716 [Unique ID], provided by the PubMed system | |
| |
|
| | 1 - 10 of 214 journal articles in the PubMed database | Email to a friend | | |
| Cummings J, Macpherson JS, Meikle I, et al.
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. [Journal Article]
Biochem Pharmacol 1996 Oct 11; 52(7):979-90.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Meikle I, Cummings J, Macpherson JS, et al.
Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. [Journal Article]
Biochem Pharmacol 1995 Jun 16; 49(12):1747-57.
Abstract | Full Citation | Find Related Articles | | Cummings J, Sumner AT, Slavotinek A, et al.
Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500. [Journal Article]
Mutat Res 1995 Aug; 344(1-2):55-62.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Meikle I, Cummings J, Macpherson JS, et al.
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505. [Journal Article]
Br J Cancer 1996 Aug; 74(3):374-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Meikle I, Cummings J, Macpherson JS, et al.
Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. [Journal Article]
Anticancer Drug Des 1995 Oct; 10(7):515-27.
Abstract | Full Citation | Find Related Articles | | Macpherson JS, Cummings J, Meikle I, et al.
Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines. [Journal Article]
Eur J Cancer 1997 Feb; 33(2):280-3.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cummings J, Meikle I, Macpherson JS, et al.
Characterization of the major metabolite of the novel topoisomerase I inhibitor NU/ICRF 505. [Journal Article]
Anticancer Drug Des 1996 Jul; 11(5):367-82.
Abstract | Full Citation | Find Related Articles | | Kusumoto H, Rodgers QE, Boege F, et al.
Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II. [Journal Article]
Cancer Res 1996 Jun 1; 56(11):2573-83.
Abstract | Full Citation | Publisher Full Text | Find Related Articles | | Cummings J, Meikle I, Macpherson JS, et al.
Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography. [Journal Article]
Cancer Chemother Pharmacol 1995; 37(1-2):103-9.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |   |
|
| |
Advertise on this site.
|
